Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine, Inc. (EDIT) reported that EVP and Chief Medical Officer Daniel Scott Ory received a grant of stock options covering 950,000 shares of common stock on September 8, 2026. The options have an exercise price of $3.03 per share and are scheduled to vest over four years, with 25% vesting on October 15, 2027 and the remaining 75% vesting in equal monthly installments through October 15, 2030. Following this grant, he holds 950,000 stock options directly, which expire on September 7, 2036.
Editas Medicine, Inc. (EDIT) had its EVP, Chief Medical Officer, Daniel Scott Ory, file an initial statement of beneficial ownership on Form 3. The filing reports no equity transactions and does not list any specific holdings or derivative positions for him as of the filing date.
Editas Medicine, Inc. (EDIT) reported that EVP and Chief Scientific Officer Linda Burkly sold 709 shares of common stock on September 3, 2026 at a weighted average price of $3.0372 per share, in an open-market transaction.
According to the company’s disclosures, the sale was effected under a durable automatic sales instruction plan adopted on July 3, 2023 and represents shares sold by Editas Medicine to satisfy tax withholding obligations arising from the vesting of restricted stock units on September 2, 2026, rather than a discretionary trade by Burkly. After this transaction, she held 61,660 shares of Editas Medicine common stock directly. The transaction price reflects a weighted average for multiple trades executed between $3.0050 and $3.0372 per share.
Editas Medicine, Inc. (EDIT) reported that its SVP, Chief Financial Officer, Amy Parison, sold 453 shares of common stock on September 3, 2026 at an average price of $3.04 per share. The transaction was executed under a durable automatic sales instruction plan adopted on July 7, 2022 to satisfy tax withholding obligations arising from restricted stock units that vested on September 2, 2026, and is described as non-discretionary. Following this sale, Parison directly holds 13,839 shares of Editas Medicine common stock.
Editas Medicine, Inc. (EDIT) director and CEO O'Neill Gilmore Neil reported selling 5,124 shares of common stock on September 3, 2026 at a weighted average price of $3.0372 per share in open-market trades. The sale was made under a Rule 10b5-1 durable automatic sales instruction plan adopted on April 13, 2022 to satisfy tax withholding obligations from restricted stock units that vested on September 2, 2026, and is described as non-discretionary. Following the sale, the reporting person directly holds 243,189 shares of Editas Medicine common stock.
Editas Medicine, Inc. (EDIT) has filed a shelf registration statement that permits the company to offer and sell up to $400,000,000 of securities, including common stock, preferred stock, debt securities, depositary shares, subscription rights, purchase contracts, warrants and units, from time to time after effectiveness.
Within this shelf, Editas has also filed a sales agreement prospectus for an at-the-market (“ATM”) program covering up to $150,000,000 of common stock to be sold through Leerink Partners LLC; these ATM shares are included in the $400,000,000 overall capacity. The company’s common stock trades on the Nasdaq Global Select Market under the symbol EDIT.
Net proceeds from any offerings may be used for general corporate purposes, including research and development, potential acquisitions, debt repayment or refinancing, working capital and capital expenditures. As of July 31, 2026, Editas had 153,580,035 shares of common stock outstanding out of 390,000,000 authorized, plus 5,000,000 authorized shares of preferred stock with none outstanding.
Editas Medicine, Inc. (EDIT) is the issuer for which Gilmore O'Neill filed a Form 144 notice to potentially sell common stock under Rule 144. The notice covers a proposed sale of 5,100 shares of Editas Medicine common stock through E*Trade, with an aggregate market value of $16,728.00 and an anticipated sale date of September 3, 2026 on NASDAQ. The securities relate to 11,294 shares acquired from restricted stock unit vesting on September 2, 2026. The filing also reports that O'Neill sold 15,380 shares of Editas Medicine common stock for $41,542.92 on June 3, 2026 during the prior three months.
Editas Medicine, Inc. (EDIT) has a notice under Rule 144 filed by officer Linda C. Burkly covering potential sales of the company’s common stock. The notice lists 700 shares of common stock held at ETrade, with a stated aggregate value of $2,296.00 and a proposed sale date of 09/03/2026. It also notes that additional shares to be sold are tied to Restricted Stock Unit vesting from issuer equity compensation on 09/02/2026 and discloses prior sales in the last three months.
ADAR1 Capital Management, LLC and its manager Daniel Schneeberger report beneficial ownership of Editas Medicine, Inc. common stock. Private investment funds managed by ADAR1 Capital Management hold 8,889,000 shares of Editas common stock, representing 5.8% of the class based on 153,530,898 shares outstanding as of June 30, 2026.
Both ADAR1 Capital Management and Mr. Schneeberger report shared voting and dispositive power over the 8,889,000 shares and no sole voting or dispositive power. Mr. Schneeberger files as a control person of ADAR1 Capital Management, which is characterized as an investment adviser. The filing is made jointly under a joint filing agreement.